Markets

Canada Nickel Company launched an in-situ carbon sequestration pilot program at its Crawford Nickel Project, collaborating with the University of Texas and funded by the U.S. Department of Energy. The project aims to accelerate CO₂ mineralization by injecting carbon-enriched water into ultramafic rock. Monitoring techniques will track the process, potentially leading to cost reductions and a model for sustainable mining. This initiative complements their existing carbonation program, supporting their net-zero carbon nickel production goal and a Zero-Carbon Industrial Cluster.

Infosys launched Infosys Topaz Fabric on November 3, 2025, a platform designed to accelerate IT service delivery using AI. The composable architecture integrates data, AI models, and pre-built applications, offering services-as-software for IT operations, transformation, and cybersecurity. Featuring over 50 AI agents, Topaz Fabric aims to automate tasks and augment human capabilities. Nu Skin is already collaborating with Infosys to enhance its IT operations using the platform’s Agent Assist features. The launch addresses the growing demand for AI-driven IT automation.

Guardian Metal Resources announced an exploration update for its Garfield gold-silver-copper project in Nevada. Rock chip sampling at the Power Line zone yielded promising results (18.3 g/t Au, 43.6 g/t Ag; 14% Cu, 145 g/t Ag). The company also staked 42 new BLM lode claims over a new Freeze North zone. A 2D IP survey identified a chargeable feature extending 500 meters beneath historic mines in the Freeze/Freeze East zones. Further geophysics and drilling are needed due to alluvial cover.

DNOW Inc. (NYSE: DNOW) will release its Q3 2025 earnings before market open on November 5, 2025, followed by an earnings call at 8:00 AM Central Time. Access the live webcast at ir.dnow.com or dial in using the provided numbers and access code 7372055. DNOW, a major energy and industrial product supplier with a focus on DigitalNOW®, serves diverse sectors and is increasingly focusing on decarbonization, energy evolution, and renewables. Analysts will look for insights into revenue growth in these emerging markets.

Faraday Future (FFAI) appointed Chris Nixon Cox as a global strategic advisor, effective November 3, 2025. Cox will focus on bolstering international expansion by fostering investor relations, navigating governmental affairs, and cultivating industrial cooperation. His role supports FFAI’s “EAI + Crypto” strategy, emphasizing AI-driven innovations and cryptocurrency integration. Cox will join the planned FFAI Global Strategic Advisory Council. This appointment aims to accelerate the company’s global deployment strategy and secure sustainable growth in the EV market.

Northern Trust expands its partnership with Avanda Investment Management to support a mandate from the Monetary Authority of Singapore (MAS) under the Equity Market Development Programme (EQDP). Northern Trust will provide investment operations outsourcing, fund administration, and risk analytics, building on a decade-long relationship. The EQDP is a S$5 billion initiative aimed at strengthening Singapore’s asset management ecosystem. Avanda’s strategy under the EQDP seeks to increase investor access to Singapore-listed equities. This collaboration underscores Northern Trust’s commitment to the Southeast Asian financial market.

Alvotech (ALVO) received a Complete Response Letter from the FDA for its AVT05 biosimilar application, citing deficiencies from a July 2025 facility inspection in Reykjavik. No other application deficiencies were noted, and the facility retains FDA approval for existing product manufacturing. Alvotech submitted a CAPA plan. The company revised its 2025 financial outlook to $570-600 million in revenue and $130-150 million adjusted EBITDA, reflecting facility investments and a temporary production slowdown. US sales of reference product Simponi were <$300M in 1H 2025; no Simponi biosimilar is approved in the US.

Caribou Biosciences (CRBU) will host a webcast on November 3, 2025, to report clinical data from the ANTLER Phase 1 trial of vispa-cel (CB-010) in relapsed/refractory B-NHL and first-time clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed/refractory multiple myeloma. The Company will also outline the Phase 3 trial design for vispa-cel and development plans for CB-011. The webcast will be available live and archived on Caribou’s website.

Tenaris (TS) has initiated the second $600 million tranche of its $1.2 billion share buyback program, scheduled from November 3, 2025, to April 30, 2026. A financial institution will execute the buyback independently, adhering to regulations and potentially purchasing shares during closed periods. Repurchased shares will be canceled, reducing the outstanding share count. The buyback, authorized by shareholders, aims to return capital, but faces risks linked to oil and gas prices.

Belite Bio (BLTE) announced that the UK’s MHRA agreed to accept a Conditional Marketing Authorization application for Tinlarebant to treat Stargardt disease, based on Phase 3 DRAGON interim analysis. The DRAGON trial enrolled 104 subjects across 11 jurisdictions. Topline final data is expected in Q4 2025, which will be submitted to MHRA for full Marketing Authorization. This regulatory milestone offers a faster route to market but depends on positive final data.